Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01298076
Registration number
NCT01298076
Ethics application status
Date submitted
31/08/2010
Date registered
17/02/2011
Date last updated
3/06/2015
Titles & IDs
Public title
Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Query!
Scientific title
A Multicentre Randomised Clinical Trial of Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema
Query!
Secondary ID [1]
0
0
2009-01024
Query!
Secondary ID [2]
0
0
NHMRC project 632667
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetic Retinopathy
0
0
Query!
Macular Edema
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - bevacizumab
Treatment: Drugs - dexamethasone
Active Comparator: AVASTIN - intravitreal bevacizumab
Active Comparator: OZURDEX - intravitreal dexamethasone
Treatment: Drugs: bevacizumab
Anti-VEGF drug for intravitreal injection
Treatment: Drugs: dexamethasone
Slow-release steroid formulation for intravitreal injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Visual acuity gain
Query!
Assessment method [1]
0
0
The comparison of the proportion of eyes gaining 10 letters of visual acuity between the bevacizumab (Avastin®) and dexamethasone (Ozurdex™) implant arms after 104 weeks.
Query!
Timepoint [1]
0
0
2 years
Query!
Secondary outcome [1]
0
0
Visual acuity change
Query!
Assessment method [1]
0
0
Change in visual acuity compared with the pre-injection level
Query!
Timepoint [1]
0
0
2 years
Query!
Secondary outcome [2]
0
0
OCT change
Query!
Assessment method [2]
0
0
Change in retinal thickness demonstrated on optical coherence tomography(OCT)
Query!
Timepoint [2]
0
0
2 years
Query!
Secondary outcome [3]
0
0
Laser requirement
Query!
Assessment method [3]
0
0
Number of laser treatments required for the treatment of macular oedema
Query!
Timepoint [3]
0
0
2 years
Query!
Secondary outcome [4]
0
0
Patient satisfaction
Query!
Assessment method [4]
0
0
Patient satisfaction with treatment
Query!
Timepoint [4]
0
0
2 years
Query!
Secondary outcome [5]
0
0
Safety
Query!
Assessment method [5]
0
0
Mean change in maximum diameter of foveal avascular zone
Incidence and severity of ocular adverse events
Incidence and severity of non ocular adverse events
Query!
Timepoint [5]
0
0
2 years
Query!
Eligibility
Key inclusion criteria
- Age >= 18 years
- Diagnosis of diabetes mellitus types 1 or 2
- Diabetic macular oedema affecting the fovea in one or both eyes (phakic or
pseudophakic) for which laser treatment is unlikely to be helpful in the opinion of
the centre chief investigator
- Best corrected visual acuity of 17-72 letters (6/12 -6/120)
- Retinal thickness > 250 micron in central 1mm subfield on Stratus (time domain) OCT
and 300 on Spectral domain OCT
- Previous macular laser treatment, or the investigator believes laser treatment is
unlikely to be helpful
- Intraocular pressure <22mmHg
- Women of childbearing potential must have a negative urine pregnancy test at the
screening visit and prior to treatment. A woman is considered of childbearing
potential unless she is postmenopausal and without menses for 12 months or is
surgically sterilised
- Written informed consent has been obtained.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Known allergy to Ozurdex, Avastin or agents used in the study
- Women who are pregnant, nursing, or planning a pregnancy, or who are of childbearing
potential and not using reliable means of contraception
- Glaucoma which is uncontrolled or is controlled but with more than one medication or
with only one medication and with glaucomatous field defects
- Loss of vision due to other causes (e.g. age related macular degeneration, myopic
macular degeneration, retinal vein occlusion)
- Macular oedema due to other causes
- An ocular condition that would prevent visual acuity improvement despite resolution of
oedema (such as foveal atrophy or substantial premacular fibrosis)
- Treatment with IVTA within the last 6 months or peribulbar TA within the last 3 months
or bevacizumab within the last 2 months.
- Cataract surgery within the last 6 months
- Retinal laser treatment within the last 3 months
- History of herpes virus infection in study eye
- Media opacity including cataract that already precludes adequate macular photography
and laser treatment, or cataract that is likely to require surgery within 2 years
- Known allergies to dexamethasone or bevacizumab
- Patient is already receiving systemic steroid treatment > 5mg prednisolone daily or
equivalent)
- Intercurrent severe disease such as septicemia, any condition which would affect
follow-up or photographic documentation (e.g. geographical, psycho-social)
- History of chronic renal failure requiring dialysis or renal transplant
- Blood pressure >180/110
- Patient has a condition or is in a situation that in the investigator's opinion may
put the patient at significant risk, may confound the study results, or may interfere
significantly with the patient's participation in the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
61
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Save Sight Institute - Sydney
Query!
Recruitment hospital [2]
0
0
South West Retina - Sydney
Query!
Recruitment hospital [3]
0
0
Centre for Eye Research Australia - Melbourne
Query!
Recruitment hospital [4]
0
0
Lions Eye Institute - Perth
Query!
Recruitment postcode(s) [1]
0
0
2001 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
2170 - Sydney
Query!
Recruitment postcode(s) [3]
0
0
3002 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6009 - Perth
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
University of Sydney
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
National Health and Medical Research Council, Australia
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The specific aims of the study are to test the following hypotheses:
- That there is a difference in change in visual acuity resulting from treatment with
intravitreal bevacizumab compared with dexamethasone implant in eyes with advanced
macular oedema
- That there is a difference in degree of resolution of macular oedema resulting from
treatment with intravitreal bevacizumab compared with dexamethasone implant in eyes with
advanced macular oedema
- That both intravitreal bevacizumab and dexamethasone implants have a manageable and
acceptable safety profile in eyes with diabetic macular oedema
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01298076
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Mark C Gillies, Professor
Query!
Address
0
0
University of Sydney
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01298076
Download to PDF